Francisco José Gómez-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco José Gómez-García has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Jose Luis Lopez Estebaranz
Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
10 shared publications - Isabel Belinchón
Department of Clinical Medicine, Miguel Hernández University, 03550 Alicante, Spain
9 shared publications - Ignacio Garcia Doval
Dermatology Department, Complexo Hospitalario Universitario de Vigo , Vigo
8 shared publications G. Carretero
Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
7 shared publicationsM. Ferrán
Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
7 shared publicationsF. Vanaclocha
Hospital Universitario 12 de Octubre, Madrid, Spain
6 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Systemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis
Central centrifugal cicatricial alopecia (CCCA) is the most common scarring alopecia among women of African descent and has been increasingly associated with systemic comorbidities, particularly cardiometabolic and fibroproliferative conditions. We conducted a PRISMA 2020 compliant systematic review and random-effects meta-analysis, prospectively registered in PROSPERO (CRD420250656067), to quantify pooled prevalence estimates and case–control associations for comorbidities in CCCA. MEDLINE and Embase were searched through 18 June 2025 for observational studies reporting comorbidities in CCCA. Twenty three studies, comprising 9,103 patients with CCCA, were eligible. Hypertension (51.9%, 95% CI 33.8–69.6), dyslipidemia (58.4%, 95% CI 29.0 82.8), obesity (37.1%, 95% CI 10.8–74.2) and uterine leiomyomas (28.0%, 95% CI 8.0–64.0) were frequently reported, with substantial heterogeneity across studies. In case–control analyses, CCCA was significantly associated with dyslipidaemia (OR 4.46, 95% CI 1.09–18.25), uterine leiomyomas (OR 2.25, 95% CI 1.10–4.58) and anxiety disorders (OR 3.27, 95% CI 1.22–8.79), whereas hypertension, obesity and thyroid disease were not consistently associated. Most included studies were retrospective and predominantly U.S.-based, contributing to methodological heterogeneity. These findings suggest that CCCA may be accompanied by a substantial burden of medically recorded systemic comorbidities and support holistic, individualized clinical assessment.
- 4 August 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessSystemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis
Central centrifugal cicatricial alopecia (CCCA) is the most common scarring alopecia among women of African descent and has been increasingly associated with systemic comorbidities, particularly cardiometabolic and fibroproliferative conditions. We conducted a PRISMA 2020 compliant systematic review and random-effects meta-analysis, prospectively registered in PROSPERO (CRD420250656067), to quantify pooled prevalence estimates and case–control associations for comorbidities in CCCA. MEDLINE and Embase were searched through 18 June 2025 for observational studies reporting comorbidities in CCCA. Twenty three studies, comprising 9,103 patients with CCCA, were eligible. Hypertension (51.9%, 95% CI 33.8–69.6), dyslipidemia (58.4%, 95% CI 29.0 82.8), obesity (37.1%, 95% CI 10.8–74.2) and uterine leiomyomas (28.0%, 95% CI 8.0–64.0) were frequently reported, with substantial heterogeneity across studies. In case–control analyses, CCCA was significantly associated with dyslipidaemia (OR 4.46, 95% CI 1.09–18.25), uterine leiomyomas (OR 2.25, 95% CI 1.10–4.58) and anxiety disorders (OR 3.27, 95% CI 1.22–8.79), whereas hypertension, obesity and thyroid disease were not consistently associated. Most included studies were retrospective and predominantly U.S.-based, contributing to methodological heterogeneity. These findings suggest that CCCA may be accompanied by a substantial burden of medically recorded systemic comorbidities and support holistic, individualized clinical assessment.
- 2 March 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (6) , 1021-1028
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Background: There are a limited number of studies comparing psoriasis patients without psoriatic arthritis (PsA) to those with arthritis. Previous results are controversial.Objectives: To perform a comparative analysis of the phenotype, baseline comorbidities, therapeutic profile and incidence of adverse events (particularly overall adverse events, infections and infestations, malignancies and psychiatric disorders) among psoriatic patients with/without PsA.Methods: All the patients on the Biobadaderm registry, a prospective inception cohort of psoriasis patients on systemic therapy, were included. Patients were divided into two groups: those with psoriasis without arthritis at the time of entry into the cohort (Pso group) and those with psoriasis and psoriatic arthritis (PsA group) at entry. Patients were followed until the censorship date (last visit in a lost‐to‐follow‐up patient, or 10 November 2015, whichever occurred first). We excluded all the patients who developed any kind of signs and/or symptoms of joint involvement during the follow‐up. A descriptive analysis was performed. We estimated incidence ratios (IRR) of adverse events during systemic treatment using a mixed‐effects Poisson regression.Results: We included 2120 patients: 1871 (88%) patients with psoriasis without arthritis and 249 (12%) with psoriasis and PsA. The follow‐up time was 5020 patients‐year in the Pso group and 762 patients‐year in the PsA group. Patients with PsA had more comorbidities, particularly hypertension and liver disease; used a higher number of systemic therapies, particularly anti‐TNFα drugs and combination therapy; and presented more adverse events (IRR adjusted = 1.29; 95% CI: [1.05–1.58]), particularly serious adverse events (IRR adjusted = 1.51; 95% CI: [1.01–2.26]) and infections/infestations (IRR adjusted = 1.88; 95% CI: [1.27–2.79]), independently of the associated comorbidities and present/past therapies.Conclusions: Given the differences between patients with psoriasis alone or with psoriasis associated with PsA, patients with psoriasis and PsA should be followed and managed more closely and with specific attention.
- 2 March 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (6) , 1021-1028
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Background: There are a limited number of studies comparing psoriasis patients without psoriatic arthritis (PsA) to those with arthritis. Previous results are controversial.Objectives: To perform a comparative analysis of the phenotype, baseline comorbidities, therapeutic profile and incidence of adverse events (particularly overall adverse events, infections and infestations, malignancies and psychiatric disorders) among psoriatic patients with/without PsA.Methods: All the patients on the Biobadaderm registry, a prospective inception cohort of psoriasis patients on systemic therapy, were included. Patients were divided into two groups: those with psoriasis without arthritis at the time of entry into the cohort (Pso group) and those with psoriasis and psoriatic arthritis (PsA group) at entry. Patients were followed until the censorship date (last visit in a lost‐to‐follow‐up patient, or 10 November 2015, whichever occurred first). We excluded all the patients who developed any kind of signs and/or symptoms of joint involvement during the follow‐up. A descriptive analysis was performed. We estimated incidence ratios (IRR) of adverse events during systemic treatment using a mixed‐effects Poisson regression.Results: We included 2120 patients: 1871 (88%) patients with psoriasis without arthritis and 249 (12%) with psoriasis and PsA. The follow‐up time was 5020 patients‐year in the Pso group and 762 patients‐year in the PsA group. Patients with PsA had more comorbidities, particularly hypertension and liver disease; used a higher number of systemic therapies, particularly anti‐TNFα drugs and combination therapy; and presented more adverse events (IRR adjusted = 1.29; 95% CI: [1.05–1.58]), particularly serious adverse events (IRR adjusted = 1.51; 95% CI: [1.01–2.26]) and infections/infestations (IRR adjusted = 1.88; 95% CI: [1.27–2.79]), independently of the associated comorbidities and present/past therapies.Conclusions: Given the differences between patients with psoriasis alone or with psoriasis associated with PsA, patients with psoriasis and PsA should be followed and managed more closely and with specific attention.
- 1 February 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (2) , 313-321
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- 1 February 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (2) , 313-321
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- 1 January 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (1) , 52-58
Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm
- 1 January 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (1) , 52-58
Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm
- 22 June 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (11) , 1942-1950
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Background: Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris.Objectives: To describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate‐to‐severe psoriasis.Methods: This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan–Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs.Results: A total of 1956 patients were included for analysis (1240 exposed to biologics during follow‐up and 1076 to classic therapies). Median follow‐up time was 3.3 years (0.0–5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.Limitations: A limitation is that this is an observational study with potential selection bias.Conclusion: Survival as a proxy measure of drug safety in psoriasis is inadequate.
- 22 June 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (11) , 1942-1950
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Background: Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris.Objectives: To describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate‐to‐severe psoriasis.Methods: This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan–Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs.Results: A total of 1956 patients were included for analysis (1240 exposed to biologics during follow‐up and 1076 to classic therapies). Median follow‐up time was 3.3 years (0.0–5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.Limitations: A limitation is that this is an observational study with potential selection bias.Conclusion: Survival as a proxy measure of drug safety in psoriasis is inadequate.
- Open Access
- 1 October 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (8) , 638-643
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
- 1 October 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (8) , 638-643
Open AccessDoes the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
- 25 September 2015
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 27 (3) , 203-209
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Background: Identifying patients likely to have very good or bad results from systemic psoriasis therapy could improve efficiency of therapy. Objective: To develop prognostic models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis. Methods: Multivariable logistic regression of a prospective multicenter cohort of psoriatic patients in clinical practice (6449 person-years of follow-up). We used as possible predictors demographic characteristics, comorbidities, characteristics of the psoriasis (type, PASI, arthritis), history of past therapy at entry in the cohort, and history of response to previous cycles while in the cohort. We defined good response to a treatment cycle as either cycle end due to disease remission or a cycle longer than 2 years that does not end later due to inefficacy in the follow-up period. Bad response to a treatment cycle was defined as a cycle that is finished due to inefficacy, based on the physician judgment, after more than 3 months of treatment. Results: Patients with fewer previous therapies, lower body mass index, older at start of therapy, and with previous history of good responses to therapy are more likely to have positive results of therapy. However, the predictive characteristics of models are poor. Conclusion: Predictive models of clinical response to systemic drugs in psoriasis with the studied variables do not seem to outperform drug selection by a dermatologist.
- 25 September 2015
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 27 (3) , 203-209
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Background: Identifying patients likely to have very good or bad results from systemic psoriasis therapy could improve efficiency of therapy. Objective: To develop prognostic models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis. Methods: Multivariable logistic regression of a prospective multicenter cohort of psoriatic patients in clinical practice (6449 person-years of follow-up). We used as possible predictors demographic characteristics, comorbidities, characteristics of the psoriasis (type, PASI, arthritis), history of past therapy at entry in the cohort, and history of response to previous cycles while in the cohort. We defined good response to a treatment cycle as either cycle end due to disease remission or a cycle longer than 2 years that does not end later due to inefficacy in the follow-up period. Bad response to a treatment cycle was defined as a cycle that is finished due to inefficacy, based on the physician judgment, after more than 3 months of treatment. Results: Patients with fewer previous therapies, lower body mass index, older at start of therapy, and with previous history of good responses to therapy are more likely to have positive results of therapy. However, the predictive characteristics of models are poor. Conclusion: Predictive models of clinical response to systemic drugs in psoriasis with the studied variables do not seem to outperform drug selection by a dermatologist.
- 3 September 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (5) , 858-864
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
Background: Psoriasis patients over 65 years‐old (elderly) constitute a growing group, underrepresented in clinical trials, and likely to be more prone to adverse events.Objective: To describe safety of systemic psoriasis therapy in patients over 65 years‐old compared to younger patients.Methods: Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were grouped in elderly (≥ 65 years old) and younger patients. Rates of adverse events were described by severity and type, and the risks compared in both groups, taking into account exposure to classic or biologic drugs, using Cox regression.Results: 175 (9.8%) of 1793 patients were elderly. Overall risk of adverse events was not higher in elderly (drug group adjusted HR 1.09 (95%CI: 0.93‐1.3)). Serious adverse events were more common in elderly (drug group adjusted HR 3.2 (95%CI: 2.0‐5.1)). Age adjusted HR of all adverse events was lower for patients exposed to biologics compared to classic drugs in the whole sample (HR 0.7 (95%CI: 0.6‐0.7)). Age did not seem to modify the effect of therapy (biologic vs. classic) in the risk of adverse events (likelihood ratio test for interaction, p = 0.12 for all adverse events, p = 0‐09 for serious adverse events).Conclusions: Serious adverse events are more common in elderly patients, although they may be related to other variants that are associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk of adverse events in the whole group. We found no differences in this association between young and elderly. These results are reassuring, although uncontrolled confounding could not be excluded as an explanation for these findings, and the power of the study to detect differences was low.
- 3 September 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (5) , 858-864
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
Background: Psoriasis patients over 65 years‐old (elderly) constitute a growing group, underrepresented in clinical trials, and likely to be more prone to adverse events.Objective: To describe safety of systemic psoriasis therapy in patients over 65 years‐old compared to younger patients.Methods: Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were grouped in elderly (≥ 65 years old) and younger patients. Rates of adverse events were described by severity and type, and the risks compared in both groups, taking into account exposure to classic or biologic drugs, using Cox regression.Results: 175 (9.8%) of 1793 patients were elderly. Overall risk of adverse events was not higher in elderly (drug group adjusted HR 1.09 (95%CI: 0.93‐1.3)). Serious adverse events were more common in elderly (drug group adjusted HR 3.2 (95%CI: 2.0‐5.1)). Age adjusted HR of all adverse events was lower for patients exposed to biologics compared to classic drugs in the whole sample (HR 0.7 (95%CI: 0.6‐0.7)). Age did not seem to modify the effect of therapy (biologic vs. classic) in the risk of adverse events (likelihood ratio test for interaction, p = 0.12 for all adverse events, p = 0‐09 for serious adverse events).Conclusions: Serious adverse events are more common in elderly patients, although they may be related to other variants that are associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk of adverse events in the whole group. We found no differences in this association between young and elderly. These results are reassuring, although uncontrolled confounding could not be excluded as an explanation for these findings, and the power of the study to detect differences was low.
- 31 March 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (1) , 156-163
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry
Background: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice.Objective: To compare the safety of biologics and classic systemic treatment.Methods: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE). We obtained raw relative risks (RR) for specific AE. Multivariate analysis consisted of Cox models adjusting for age, gender, chronic hepatic disease and previous cancer.Results: A total of 1030 patients received biologics (2061 AE in 3681 person‐years), 926 patients classic systemic drugs (1015 AE in 1517 person‐years). Ninety‐three per cent of AE in both groups were non‐serious, 6% serious and 0.003% fatal. The age‐ and gender‐adjusted hazard ratio of AE was lower in the biologics group [hazard ratio 0.6 (95% CI: 0.5–0.7)].We found no differences in rates of serious and mortal AE. Some system organ class AE rates differed between both groups. As limitations: Prescription bias might affect the incidence of AE in both groups. Association of drug and AE was based on timing: associations might not be causal.Conclusion: Patients receiving biologics had lower risk of AE. We did not find differences in the risk of serious or fatal AE.
- 31 March 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (1) , 156-163
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry
Background: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice.Objective: To compare the safety of biologics and classic systemic treatment.Methods: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE). We obtained raw relative risks (RR) for specific AE. Multivariate analysis consisted of Cox models adjusting for age, gender, chronic hepatic disease and previous cancer.Results: A total of 1030 patients received biologics (2061 AE in 3681 person‐years), 926 patients classic systemic drugs (1015 AE in 1517 person‐years). Ninety‐three per cent of AE in both groups were non‐serious, 6% serious and 0.003% fatal. The age‐ and gender‐adjusted hazard ratio of AE was lower in the biologics group [hazard ratio 0.6 (95% CI: 0.5–0.7)].We found no differences in rates of serious and mortal AE. Some system organ class AE rates differed between both groups. As limitations: Prescription bias might affect the incidence of AE in both groups. Association of drug and AE was based on timing: associations might not be causal.Conclusion: Patients receiving biologics had lower risk of AE. We did not find differences in the risk of serious or fatal AE.
- 15 July 2013
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (7) , 907-914
Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
Background: There are few data on the prevalence of obesity in the general psoriasis population and on the real impact of obesity on the management of psoriasis patients in the clinical setting.Objectives: To evaluate the prevalence of overweight and obesity in patients with moderate‐to‐severe psoriasis compared to the general population and to assess the relationship between Body Mass Index (BMI) and the risk of discontinuing treatment.Methods: Patients registered on Biobadaderm, a prospective registry, were grouped according the different categories of BMI and compared to the general Spanish population. Drug survival was analysed considering only drug withdrawal due to lack of effectiveness, remission and adverse events.Results: A total of 1162 moderate‐to‐severe psoriasis patients on systemic conventional or biological treatment were recruited. The prevalence of obesity was found to be significantly higher in psoriasis patients than in the general Spanish population (P < 0.001). In multivariate analysis a 5‐unit increase in BMI, similar to a change in BMI category from normal weight to overweight and from overweight to obesity, was associated with a 12% increased risk of discontinuing therapy due to lack of effectiveness (HR 1.12, 95% CI: 1.01–1.24) and with a 17% increased risk of having an adverse event (HR 1.17, 95% CI: 1.02–1.36), both independently of the drug used.Conclusions: Patients with moderate‐to‐severe psoriasis had a higher prevalence of obesity than the general population. Increased BMI was associated with an increased risk of treatment discontinuation due to lack of effectiveness and a higher risk of adverse events.
- 15 July 2013
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (7) , 907-914
Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
Background: There are few data on the prevalence of obesity in the general psoriasis population and on the real impact of obesity on the management of psoriasis patients in the clinical setting.Objectives: To evaluate the prevalence of overweight and obesity in patients with moderate‐to‐severe psoriasis compared to the general population and to assess the relationship between Body Mass Index (BMI) and the risk of discontinuing treatment.Methods: Patients registered on Biobadaderm, a prospective registry, were grouped according the different categories of BMI and compared to the general Spanish population. Drug survival was analysed considering only drug withdrawal due to lack of effectiveness, remission and adverse events.Results: A total of 1162 moderate‐to‐severe psoriasis patients on systemic conventional or biological treatment were recruited. The prevalence of obesity was found to be significantly higher in psoriasis patients than in the general Spanish population (P < 0.001). In multivariate analysis a 5‐unit increase in BMI, similar to a change in BMI category from normal weight to overweight and from overweight to obesity, was associated with a 12% increased risk of discontinuing therapy due to lack of effectiveness (HR 1.12, 95% CI: 1.01–1.24) and with a 17% increased risk of having an adverse event (HR 1.17, 95% CI: 1.02–1.36), both independently of the drug used.Conclusions: Patients with moderate‐to‐severe psoriasis had a higher prevalence of obesity than the general population. Increased BMI was associated with an increased risk of treatment discontinuation due to lack of effectiveness and a higher risk of adverse events.